- Marc Lustig is BriaCell’s largest shareholder
- Mr. Lustig is a highly regarded investor, entrepreneur, and corporate finance veteran with a deep understanding of the life sciences industry
- Marc holds MSc and MBA degrees from McGill University
- BriaCell is an immuno-oncology focused biotechnology company
- BriaCell Therapeutics Corp. (BCT) is down 1.18 per cent, trading at C$8.41 per share at 10:45 am ET
BriaCell Therapeutics (BCT) welcomes Mr. Marc Lustig to the company’s Board of Directors, effective September 1, 2021.
Marc, through his investment company L5 Capital Inc., owns 1,530,000 common shares of BriaCell, representing 10.0 per cent of BriaCell’s issued and outstanding common shares.
“It is our pleasure to welcome Marc to our Board of Directors at this transformative phase for BriaCell,” remarked Jamieson Bondarenko, BriaCell’s Chairman of the Board.
“Marc’s exemplary expertise in both corporate finance and the pharmaceutical industry will be invaluable to our capital markets and corporate partnership strategies as we advance our novel cancer therapeutics.”
“BriaCell’s novel technology has the potential to change the way we treat cancer,” said Marc Lustig.
“As the largest shareholder and now a director, I have been thoroughly impressed by the BriaCell team’s passion and commitment to bring new treatment options to cancer patients who do not respond to current therapies. I look forward to working with the team on their strategic capital and partnering activities to drive significant value for shareholders.”
Mr. Lustig is a highly regarded investor, entrepreneur, and corporate finance veteran with a deep understanding of the life sciences industry, including biotechnology and pharmaceuticals, as well as the legal cannabis industry.
Marc holds MSc and MBA degrees from McGill University and his professional experience includes working at Merck & Co. His capital markets career includes roles in biotech equity research, corporate finance and as Head of Capital Markets.
Mr. Lustig was the founder and CEO of Origin House which was sold to Cresco Labs Inc. in 2020 where he currently serves as a director.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
BriaCell Therapeutics Corp. (BCT) is down 1.18 per cent, trading at C$8.41 per share at 10:45 am ET.